Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection

Chemotherapy
A Di FilippoG P Novelli

Abstract

The aim of the study was to verify the therapeutic response of vancomycin in methicillin-resistant staphylococcus infection (MRSA/ MRCNS) administered according to two different methods (intermittent infusion vs. continuous infusion). Experimental plan: retrospective study; study environment: university hospital, two intensive care units. Twenty-five critically ill patients submitted to antibiotic treatment with vancomycin for infection from MRSA/MRCNS were studied. The patients, who were classified according to SAPS II scores, were divided into two groups: group A (n = 14): dose of vancomycin of 0.5 g x 4/day and group B (n = 11): dose of 2 g/day of vancomycin administered in a continuous infusion. Before the antibiotic therapy was started (T1) and prior to its end (T2), the following parameters were evaluated: degree of impairment of the main organs and systems by means of sepsis-related organ failure assessment score (SOFA) and count of the white blood cells (WBC). The length of the hospital stay during intensive care was calculated for both groups (statistics: Student t test). No significant differences were found in the SAPS II scores and in the length of the hospital stay. In a comparison of the T1 and T2 results, we note...Continue Reading

Citations

Apr 2, 2008·Current Infectious Disease Reports·Tze-Peng LimVincent H Tam
Jun 1, 1999·The Journal of Antimicrobial Chemotherapy·F ThalhammerH Burgmann
Oct 27, 2011·The Journal of Antimicrobial Chemotherapy·Maria Adriana CataldoNicola Petrosillo
Jul 11, 2008·Current Opinion in Critical Care·Jason A RobertsJordi Rello
May 23, 2003·Antimicrobial Agents and Chemotherapy·Baudouin BylJean-Pierre Thys
Jul 4, 2012·Annals of Intensive Care·Bruno Van HerendaelMargareta Ieven
Jan 1, 2010·Infection and Drug Resistance·Andres Beiras-FernandezFlorian Weis
Jun 12, 2001·Drugs·F Alvarez-LermaS Grau
Nov 13, 2004·Intensive Care Medicine·Rina MehrotraMark Palazzo
Jun 1, 2012·European Journal of Trauma and Emergency Surgery : Official Publication of the European Trauma Society·D D YehK Lunghi
Sep 2, 1998·Journal of Pharmaceutical Sciences·M KusamaT Iga
Dec 15, 2015·International Journal of Antimicrobial Agents·Jing-Jing HaoJian-Xin Zhou
Dec 7, 2010·International Journal of Antimicrobial Agents·Francesco Scaglione
Jul 16, 2008·International Journal of Antimicrobial Agents·Francesco Scaglione, Luca Paraboni
Feb 23, 2007·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M SchwabeC F Waller
Aug 25, 2005·Archivos de bronconeumología·C M LunaUNKNOWN Grupo Argentino-Latino Americano de estudio de la Neumonía Nosocomial (GALANN)
Apr 18, 2000·Critical Care Clinics·J L VincentR Moreno
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Scott D Pope, Andrew M Roecker
Mar 31, 2015·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Marco FalconeMario Venditti
Aug 30, 2019·International Journal of Psychiatry in Clinical Practice·Yu-Chi HuangLiang-Jen Wang
Sep 25, 2003·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Lynn Hadaway, Stanley N Chamallas
May 21, 2020·Therapeutic Drug Monitoring·Erik M van MaarseveenArthur R H van Zanten
Feb 7, 2013·The Annals of Pharmacotherapy·V Paul DiMondi, Kelly Rafferty
Aug 6, 2009·Journal of Chemotherapy·T Mazzei, A Novelli
Apr 9, 2002·Journal of Chemotherapy·M AntonelliG Deangelis

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.